Drug Trial Radar · NCT01045421
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Last checked: Nov 19, 2026Latest source record: Aug 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
273
Actual
Start
Feb 2010
Primary completion
May 2013
Study completion Apr 2014
Sponsor
- Lead sponsor
- Millennium Pharmaceuticals, Inc.Takeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 11, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.
Conditions
- Advanced Nonhematological Malignancies
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Metastatic Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Gastroesophageal Adenocarcinoma
Interventions
MLN8237 (Alisertib)Drug
Phase 1: MLN8237 will be administered orally twice a day on a 7-day dosing schedule Phase 2: MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Phase 1: Cycle 1 Day 1 to Cycle 2 Day 21
- Phase 2: Percentage of Participants With Objective ResponseTime frame: Baseline until complete response or partial response, assessed every 2 cycles up to end of study (up to 50 cycles)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Houston, Texas
Site not named
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.